A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Inclusion Criteria:

Age at least 18 years.
Documented evidence of NSCLC (locally advanced, unresectable, Stage III)
Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.
World Health Organisation (WHO) Performance Status of 0 to 1.
Estimated life expectancy of more than 12 weeks.

Exclusion Criteria:

Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
Active or prior autoimmune disease or history of immunodeficiency.
Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.
Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).